Hui He

Dr. Hui He

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XZXiuli Zhang
Xiuli Zhang
HHHui He
Hui He
DLDan Liang
Dan Liang
XZXiuli Zhang
Xiuli Zhang
WLWei Liang
Wei Liang
JMJianfei Ma
Jianfei Ma
Diabetic nephropathy (DN) is a serious diabetic complication with renal hypertrophy and expansion of extracellular matrices in renal fibrosis. Epithelial-to-mesenchymal transition (EMT) of renal tubular epithelial cells may be involved in the main mechanism. Berberine (BBR) has been shown to have antifibrotic effects in liver, kidney and lung. However, the mechanism of cytoprotective effects of BBR in DN is still unclear. In this study, we investigated the curative effects of BBR on tubulointerstitial fibrosis in streptozotocin (STZ)-induced diabetic mice and the high glucose (HG)-induced EMT in NRK 52E cells. We found that BBR treatment attenuated renal fibrosis by activating the nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway in the diabetic kidneys. Further revealed that BBR abrogated HG-induced EMT and oxidative stress in relation not only with the activation of Nrf2 and two Nrf2-targeted antioxidative genes (NQO-1 and HO-1), but also with the suppressing the activation of TGF-β/Smad signaling pathway. Importantly, knockdown Nrf2 with siRNA not only abolished the BBR-induced expression of HO-1 and NQO-1 but also removed the inhibitory effect of BBR on HG-induced activation of TGF-β/Smad signaling as well as the anti-fibrosis effects. The data from present study suggest that BBR can ameliorate tubulointerstitial fibrosis in DN by activating Nrf2 pathway and inhibiting TGF-β/Smad/EMT signaling activity.

14 July 2015 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
HHHui He
Hui He
ZLZhao-Qian Liu
Zhao-Qian Liu
XLX. Li
X. Li
JYJ. Y. Yin
J. Y. Yin
MZM. Zhai
M. Zhai
HZH. H. Zhou
H. H. Zhou
What is known and objective Identification of biomarkers that could predict high‐dose cytarabine (Ara‐C) efficacy and toxicity is a key issue in individualized therapy. The aim of our study was to evaluate the influence of cytidine deaminase (CDA) single nucleotide polymorphisms (SNPs) ‐451G>A (rs532545), 435C>T (rs1048977) and ‐33delC (rs3215400) on treatment outcome in patients with relapsed acute myeloid leukaemia (AML) after high‐dose Ara‐C chemotherapy. Methods In total, 173 patients with relapsed AML, treated with high‐dose Ara‐C chemotherapy, were genotyped for three polymorphisms in CDA gene using the allele‐specific matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry assays. Binary logistic regression was used to evaluate the influence of selected polymorphisms on tumour response and occurrence of treatment‐related toxicity. Results and discussion The CC genotype at ‐33delC, a promoter polymorphism, increased the odds of overall response rate (odds ratio [OR] = 5·125; 95% confidence intervals (CI) = 2·446–10·74; P = 0·0008) and grade ≥3 infection toxicity incidence rate (OR = 3·572; 95% CI = 1·68–7·594; P = 0·003). In multivariable analysis, this polymorphism was a potential independent prognostic marker for the risk of overall response (P = 0·011), but not grade ≥3 infection toxicity incidence rate (P = 0·49). Two other polymorphisms, ‐451G>A and 435C>T, did not influence treatment outcome, including overall response rate, infection toxicity and nausea/vomiting, in patients with relapsed AML (P > 0·05). What is new and conclusion The findings suggest that CDA ‐33delC variant might be a potential marker for predicting treatment outcome in Chinese patients with relapsed AML given high‐dose cytarabine chemotherapy.

28 November 2025 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
YYYuan-Jiao Yang
Yuan-Jiao Yang
HYHan-Bing Yan
Han-Bing Yan
WLWen-Tao Liu
Wen-Tao Liu
ZYZhi-Chao Yang
Zhi-Chao Yang
XWXiao-Hui Wang
Xiao-Hui Wang
HHHui He
Hui He
Background: This study aimed to construct a prediction model for the occurrence of venous thromboembolism (VTE) in patients hospitalized with coronary heart disease (CHD) using machine learning algorithms. Methods: Clinical data were from the medical records of CHD patients admitted to tertiary hospitals in eastern Liaoning Province between 2019 and 2024. Five machine learning algorithms—random forest (RF), classification and regression tree (CART), logistic regression (LR), logistic regression + least absolute shrinkage and selection operator (LR + LASSO), and extreme gradient boosting (XGBoost)—were used to construct predictive models. The area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy were comparison metrics between different models. Results: A total of 3113 CHD inpatients were included in the study. In the internal validation set, XGBoost had the highest AUC (0.704), sensitivity (0.708), and accuracy (0.692), and RF had the highest specificity (0.706). In the time external validation set, LR + LASSO had the highest AUC (0.649), the highest specificity (0.683) for RF, and the highest sensitivity (0.682) and accuracy (0.656) for XGBoost. D-dimer, Age, and Neutrophil Count (NEUT) were the three most important relevant indicators. Conclusion: The prediction model based on machine learning algorithms for the occurrence of VTE in CHD inpatients has a specific diagnostic value. The prediction model constructed by LR + LASSO and XGBoost is more effective than the models constructed by other methods. The results of this study can provide research ideas for the clinical prevention and treatment of VTE events occurring in CHD inpatients.

10 August 2023 in Research Square
Verified
Preprint
Open access
PDF file
HHHui He
Hui He
WLWen-Tao Liu
Wen-Tao Liu
ZYZhi-Chao Yang
Zhi-Chao Yang
XWXiao-Hui Wang
Xiao-Hui Wang
YYYuan-Jiao Yang
Yuan-Jiao Yang
HHHui He
Hui He
Background Venous thromboembolism (VTE) is a multifactorial disease that is associated with long-term morbidity, dysfunction, and mortality. Although numerous studies have reported on the incidence and risk factors of VTE in hospitalized patients, the reported results vary due to the complexity of the disease and differences in genetic characteristics, social environment, and disease spectrum. Therefore, the aim of this study was to investigate the incidence, clinical features, and risk factors for VTE in hospitalized patients. Methods A cross-sectional study was conducted at Benxi Central Hospital to select patients hospitalized between January and December 2021. All patients underwent Doppler ultrasound, and medical data, including demographic characteristics, past medical history, comorbidities, and hematologic indicators, were collected from the Benxi Clinical Biobank. Chi-square tests and logistic regression analysis were employed to identify independent risk factors. Results A total of 1200 in-patients were eligible for inclusion in the study. The prevalence of venous thromboembolism was 21.4%. 224 patients developed DVT alone, 12 patients developed PE alone, and 14 patients developed both DVT and PE. Of the 238 patients with DVT in the lower limbs (with or without PE), distal DVT was more common than proximal DVT (64.7%vs20.2%). In multifactorial analysis, six variables are independent risk factors for VTE:Diabetes,OR,1.659,(1.100-2.501, P = 0.016);History of confirmedVTE,OR,6.497,(3.505–12.041,P = 0.000);Central venous catheterization,OR,2.605,(1.583–4.289,P = 0.000);Age,OR,1.035,(1.022–1.048,P = 0.000);HGB,OR,0.993,(0.987-1.000, P = 0.042);Unilateral limb pitting oedema,OR,5.307,(3.506–8.033, P = 0.000);Bilateral limb pitting oedema,OR,1.701,(1.081–2.676,P = 0.022). Conclusion The incidence of VTE among hospitalized patients in Benxi region is relatively high. Identifying relevant risk factors allows for early screening of at-risk populations. In order to reduce prevalence, and more prospective studies are needed to comprehensively develop individualised clinical prediction tools for VTE.